■胰岛素样生长因子-1(IGF-1)具有多种神经营养作用,包括神经发生,髓鞘再生和突触发生,是神经元可塑性的有效调节剂。尽管多项研究已经调查了IGF-1在抑郁症相关疾病中的作用,很少有研究关注首次明确诊断为抑郁症的患者,这些患者以前从未使用过抗抑郁药。因此,这项研究调查了首发和未服用药物的抑郁症患者,以补充目前关于抑郁症中IGF-1水平的证据。
■本研究由两部分组成。在第一部分,60例首次发作和首次用药的抑郁症患者和60例年龄相匹配的对照组,性别,和BMI从芜湖市第四医院门诊部招募,和社区。采用病例对照法比较两组间血清IGF-1水平的差异。在第二部分,通过数据库筛选13项病例对照研究进行荟萃分析,以验证结果的可靠性。
■病例对照研究的结果表明,与健康对照组相比,首次发作和未用药抑郁症患者的血清IGF-1水平显着升高(p<0.05)。尽管诊断为MDD的男性和女性之间没有显着差异,抑郁症患者血清IGF-1水平与年龄无显著相关性,IGF-1水平与抑郁症严重程度无显著相关性。荟萃分析证实了这些发现,并证明MDD患者的IGF-1水平明显高于健康对照组。
■首次发作和未服用药物的抑郁症患者的IGF-1水平更高,但在IGF-1与抑郁症相关的研究中排除混杂因素必须严格考虑,需要更多的研究来充分了解IGF-1在抑郁症中的关键作用。
■PROSPERO,标识符CRD42023482222。
UNASSIGNED: Insulin-like growth factor-1 (IGF-1) has a variety of neurotrophic effects, including neurogenesis, remyelination and synaptogenesis, and is an effective regulator of neuronal plasticity. Although multiple studies have investigated IGF-1 in depression-related disorders, few studies have focused on patients with a first episode of clearly diagnosed depression who had never used antidepressants before. Therefore, this study investigated first-episode and drug-naïve patients with depression to supplement the current evidence around IGF-1 levels in depressive disorders.
UNASSIGNED: This study consisted of two parts. In the first part, 60 patients with first-episode and drug-naïve depression and 60 controls matched for age, sex, and BMI were recruited from the outpatient department of the Fourth Hospital of Wuhu City, and the community. The
case-control method was used to compare differences in serum IGF-1 levels between the two groups. In the second part, 13
case-control studies were screened through the database for meta-analysis to verify the reliability of the results.
UNASSIGNED: Results of the
case-control study demonstrated that serum IGF-1 levels are significantly higher in patients with first-episode and drug-naïve depression compared to healthy controls (p<0.05), although there was no significant difference between men and women with diagnosed MDD, there was no significant correlation between serum IGF-1 level and age in patients with depression and no significant correlation between IGF-1 level and the severity of depression. The meta-analysis corroborates these findings and demonstrated that IGF-1 levels are significantly higher in MDD patients than in healthy controls.
UNASSIGNED: Patients with first-episode and drug-naïve depression have higher IGF-1 levels, but the exclusion of confounding factors in studies of IGF-1 as it relates to depressive disorders must be taken into consideration strictly, and additional research is needed to fully understand the critical role of IGF-1 in depression.
UNASSIGNED: PROSPERO, identifier CRD42023482222.